alexa Alzheimer’s Disease Drug Discovery

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Alzheimer’s Disease Drug Discovery

Alzheimer’s disease (AD) is one of the most expensive human diseases and a leading cause of disability and death among elderly. As the elderly population is growing worldwide, AD will soon become a major human healthcare challenge if it remains incurable. The currently available therapeutics for AD only acts to lower its symptoms without any effect on the actual underlying pathology In recent years, however, significant amount of research has been focused on finding the so called "neuroprotective" agents, therapeutics that can stop or slow the disease progress by targeting special molecular mechanisms in the AD pathology process. Yet more futuristic are approaches that can rebuild the damaged tissue, called as "regenerative agents". These two approaches together are known as "disease-modifying approaches". According to its definition, a disease modifying treatment should not only interfere with the underlying pathological mechanisms leading to neuronal dysfunction and loss in AD, but it should also lead to significant clinical improvement of the patient.


Citation: Nazem A (2014) Alzheimer’s Disease Drug Discovery is Misled by Wrong Animal Models . J Gerontol Geriat Res 3:e127. doi: 10.4172/2167-7182.1000e127

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger